As a Free StocksGuide user, you can view scores for all 7,029 stocks worldwide.
25 Analysts have issued a Jazz Pharmaceuticals Plc forecast:
25 Analysts have issued a Jazz Pharmaceuticals Plc forecast:
| Jun '25 | 
    +/-
   
    %
   | ||
| Revenue | 4,087 4,087 | 
      
        
        5%
      
      
        
        5%
      
 | |
| Gross Profit | 3,625 3,625 | 
      
        
        4%
      
      
        
        4%
      
 | |
| EBITDA | 1,247 1,247 | 
      
        
        1%
      
      
        
        1%
      
 | |
| EBIT (Operating Income) EBIT | 614 614 | 
      
        0%
      
      
        0%
      
 | |
| Net Profit | -405 -405 | 
      
        
        203%
      
      
        
        203%
      
 | |
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.
| Head office | Ireland | 
| CEO | Bruce Cozadd | 
| Employees | 2,800 | 
| Founded | 2005 | 
| Website | www.jazzpharma.com | 
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


